"Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials" by James Larkin

Selected Works of Walter J. Urba, MD, PhD

Article

Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials

JAMA Oncology (2015)

James Larkin, The Royal Marsden NHS Foundation Trust
Christopher D. Lao, University of Michigan
Walter J. Urba, Providence Portland Medical Center
David F. McDermott, Beth Israel Deaconess Medical Center
Christine Horak, Bristol-Myers Squibb
Joel Jiang, Bristol-Myers Squibb
Jedd D. Wolchok, Cornell University

Link

Disciplines

Medicine and Health Sciences,
Pathology and
Oncology

Publication Date

July 1, 2015

DOI

10.1001/jamaoncol.2015.1184

Citation Information

James Larkin, Christopher D. Lao, Walter J. Urba, David F. McDermott, et al.. "Efficacy and Safety of Nivolumab in Patients With BRAF V600 Mutant and BRAF Wild-Type Advanced Melanoma: A Pooled Analysis of 4 Clinical Trials" JAMA Oncology Vol. 1 Iss. 4 (2015) p. 433 - 440
Available at: http://works.bepress.com/walter-urba/122/